Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 18/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5341561 | 0.90 | IKBKB (1.00) | IKBKB | |
| SCHEMBL5257160 | 0.90 | IKBKB (0.67) | IKBKB | |
| SCHEMBL5254936 | 0.90 | IKBKB (0.76) | IKBKB | |
| SCHEMBL5255028 | 0.90 | IKBKB (0.66) | IKBKB | |
| SCHEMBL5257003 | 0.89 | IKBKB (0.65) | IKBKB | |
| SCHEMBL14532978 | 0.89 | IKBKB (0.66) | IKBKBALDH1A1 | |
| SCHEMBL5256635 | 0.89 | IKBKB (0.65) | IKBKB | |
| SCHEMBL5255619 | 0.88 | IKBKB (0.64) | IKBKB | |
| SCHEMBL5343959 | 0.88 | IKBKB (0.79) | IKBKB | |
| SCHEMBL5255819 | 0.87 | IKBKB (0.78) | IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427706-B1 | SUBSTITUTED PYRAZOLO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORP (US) | 2007-05-30 | — | — | EP | claimed |
| US-7211597-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2007-05-01 | — | — | US | claimed |
| US-20030114432-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-06-19 | — | — | US | claimed |
| EP-1427706-B1 | SUBSTITUTED PYRAZOLO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORP (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1427706-B1 | SUBSTITUTED PYRAZOLO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORP (US) | 2007-05-30 | — | — | EP | disclosed |
| US-7211597-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2007-05-01 | — | — | US | disclosed |
| US-7211597-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2007-05-01 | — | — | US | disclosed |
| US-7211597-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2007-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114432-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | IKBKB 55/4885ALDH1A1 897/4885POLB 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.